Published in Vasc Health Risk Manag on January 01, 2007
Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertension. J Hypertens (2010) 1.43
Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter? Eur Heart J (2008) 1.10
Molecular mechanisms of pulmonary arterial remodeling. Mol Med (2014) 1.05
Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease. Br J Haematol (2009) 1.03
Endothelin. Pharmacol Rev (2016) 0.95
The role of endothelin-1 in pulmonary arterial hypertension. Glob Cardiol Sci Pract (2014) 0.89
New lines in therapy of Raynaud's phenomenon. Rheumatol Int (2008) 0.84
The adrenergic system in pulmonary arterial hypertension: bench to bedside (2013 Grover Conference series). Pulm Circ (2015) 0.78
Molecular modeling, quantum polarized ligand docking and structure-based 3D-QSAR analysis of the imidazole series as dual AT(1) and ET(A) receptor antagonists. Acta Pharmacol Sin (2013) 0.77
Substrate-specific pharmacokinetic interaction between endothelin receptor antagonists and phosphodiesterase-5 inhibitors--assembling the clues. Br J Clin Pharmacol (2009) 0.75
Pediatric Cardiac Intensive Care Society 2014 Consensus Statement: Pharmacotherapies in Cardiac Critical Care Pulmonary Hypertension. Pediatr Crit Care Med (2016) 0.75
Anti-hypotensive treatment and endothelin blockade synergistically antagonize exercise fatigue in rats under simulated high altitude. PLoS One (2014) 0.75
Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med (1991) 13.21
Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med (1996) 11.76
Bosentan therapy for pulmonary arterial hypertension. N Engl J Med (2002) 11.18
Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med (2005) 9.27
A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med (1996) 8.02
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet (2001) 6.88
Treatment of pulmonary arterial hypertension. N Engl J Med (2004) 6.88
Primary pulmonary hypertension. A national prospective study. Ann Intern Med (1987) 6.80
Pulmonary arterial hypertension. N Engl J Med (2004) 6.69
Clinical classification of pulmonary hypertension. J Am Coll Cardiol (2004) 5.87
Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med (1993) 4.91
An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med (1992) 4.74
Regulatory functions of the vascular endothelium. N Engl J Med (1990) 4.72
Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol Sci (1990) 4.30
Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med (1998) 4.01
Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med (1995) 3.70
Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol (2004) 3.63
Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med (1994) 2.75
Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest (2004) 2.74
Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med (2003) 2.64
Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol (2006) 2.42
Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med (1999) 2.21
The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther (2001) 2.10
The endothelin system in pulmonary arterial hypertension. Cardiovasc Res (2004) 2.09
Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest (2004) 2.00
Vasodilator therapy for primary pulmonary hypertension in children. Circulation (1999) 2.00
Evaluation and management of the patient with pulmonary arterial hypertension. Ann Intern Med (2005) 1.91
Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol (2005) 1.82
Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest (1993) 1.80
Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum (1986) 1.72
Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet (2004) 1.66
Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol (1995) 1.65
Contribution of mrp2 in alterations of canalicular bile formation by the endothelin antagonist bosentan. J Hepatol (2002) 1.59
Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest (2001) 1.49
Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol (1997) 1.46
The pathophysiology of failure in acute right ventricular hypertension: hemodynamic and biochemical correlations. Circulation (1981) 1.43
HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med (1997) 1.35
Endothelin receptors and calcium signaling. FASEB J (1995) 1.30
Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. Chest (2000) 1.27
Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol (2004) 1.22
Primary pulmonary hypertension associated with the use of fenfluramine derivatives. Chest (1998) 1.22
Risk factors for pulmonary arterial hypertension. Clin Chest Med (2001) 1.20
Clinical primary pulmonary hypertension: three pathologic types. Circulation (1977) 1.15
Pulmonary arterial hypertension. Proc Am Thorac Soc (2006) 1.12
Endothelin 1: mitogenic activity on pulmonary artery smooth muscle cells and release from hypoxic endothelial cells. Proc Soc Exp Biol Med (1992) 1.08
Increased lung endothelin-1 production in rats with idiopathic pulmonary hypertension. Am J Physiol (1992) 1.08
Endothelin-1 in the lungs of patients with pulmonary hypertension. Cardiovasc Res (1997) 1.07
The selective endothelin ETA receptor antagonist BQ123 antagonizes endothelin-1-mediated mitogenesis. Eur J Pharmacol (1992) 1.01
Role of hemodynamics in pulmonary vascular remodeling: implications for primary pulmonary hypertension. Am J Respir Crit Care Med (1999) 1.01
Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest (2008) 1.00
Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology (2000) 1.00
Endothelin-1 in primary pulmonary hypertension and the Eisenmenger syndrome. Am J Cardiol (1993) 0.94
Bosentan for the treatment of pulmonary arterial hypertension. Ann Pharmacother (2003) 0.90
Endothelin-receptor antagonists in pulmonary hypertension. Lancet (2001) 0.90
Ca/CaM-stimulated and cGMP-specific phosphodiesterases in vascular and non-vascular tissues. Adv Exp Med Biol (1991) 0.90
M&B 22948, a cGMP phosphodiesterase inhibitor, is a pulmonary vasodilator in lambs. Am J Physiol (1993) 0.90
Moderation of hypoxic vasoconstriction by infused arachidonic acid: role of PGI2. J Appl Physiol Respir Environ Exerc Physiol (1980) 0.85
Ambrisentan for pulmonary arterial hypertension. Future Cardiol (2005) 0.85
Endothelial dysfunction providing the basis for the treatment of pulmonary hypertension: Giles F. Filley lecture. Chest (1998) 0.83
Drug treatment of pulmonary arterial hypertension: current and future agents. Drugs (2005) 0.79
Ambrisentan (Myogen). Curr Opin Investig Drugs (2002) 0.77
Current therapy of pulmonary hypertension. Herz (2005) 0.77